Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.

  • M E Evangelopoulos, E Andreadou, +6 authors Constantinos Kilidireas
  • Published 2017 in Journal of the neurological sciences

Abstract

Neuromyelitis optinca (NMO) represents a serious demyelinating disease of the central nervous system selectively attacking the spinal cord and optic nerve. Early differential diagnosis from multiple sclerosis is of vital importance, as NMO mandates immunosuppressive and not immunomodulatory treatment. Rituximab has been recently introduced as a treatment… (More)
DOI: 10.1016/j.jns.2016.11.016

Cite this paper

@article{Evangelopoulos2017TreatmentON, title={Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.}, author={M E Evangelopoulos and E Andreadou and Georgios Koutsis and V Koutoulidis and Maria C Anagnostouli and Paraskevi Zacharoula Katsika and D S Evangelopoulos and Ioannis Evdokimidis and Constantinos Kilidireas}, journal={Journal of the neurological sciences}, year={2017}, volume={372}, pages={92-96} }